The story of Sildenafil presents a interesting case for observers in the drug sector. While initially a tremendous success, creating huge profits, the intellectual property lapse and the subsequent arrival of cheaper competitors have considerably impacted income. This presents questions about the ongoing sustainability of analogous medication pr… Read More